The conversation also highlights Texas’ decision to invest $50 million in clinical trials studying ibogaine, one of the largest public investments in psychedelic research to date. Hubbard describes the legislative effort behind the initiative and outlines broader plans to encourage similar research partnerships in other states as scientists and policymakers explore new strategies for addressing addiction and mental health challenges.
Audio-only Podcasts
Newt's World: Episode 858 - Ibogaine – A Breakthrough Treatment for Addiction
May 25, 2025
In this episode of Newt’s World, former Speaker of the House Newt Gingrich speaks with Bryan Hubbard, Executive Director of Americans for Ibogaine, about the growing effort to study ibogaine as a potential treatment for addiction, traumatic brain injury, and other neurological conditions. Hubbard discusses how his experiences addressing the opioid crisis in Kentucky led him to focus on advancing research into alternative treatment approaches.